Rodin Therapeutics Email Format
Biotechnology ResearchMassachusetts, United States0-1 Employees
Rodin Therapeutics is a biotechnology research company based in Cambridge, Massachusetts, focused on epigenetic regulation of neuronal function to treat brain diseases. It pursues targeted epigenetic regulation through HDAC complex modulation to restore synaptic function and synaptic resilience in degenerative brain diseases. The organization is extremely small, with a reported workforce of 0 to 1 employees. The company has a history of leadership and financing activities, including appointing a chief financial officer in 2019 and completing a Series B financing in 2017. In 2019, Alkermes, Inc. acquired Rodin Therapeutics in a deal valued around 950 million dollars. The website address is https://rodintherapeutics.com.